Artículos del autor

solaci

Day 3

REPRISE II: LOTUS valve for percutaneous aortic valve replacement

The aim of this study was to evaluate the safety and efficacy of the new device in...
solaci -
Day 3

GIANT: Evaluation of the genetic profile of CYP2C19 in patients undergoing primary angioplasty

The aim of this study was to evaluate the clinical impact resistance thienopyridines through genetic analysis of...
solaci -
Day 3

DUTCH PEERS: Everolimus DES versus zotarolimus DES

This study randomized 1:1,  906 patients to receive zotarolimus-eluting stent and 905 patients to receive everolimus-eluting stent....
solaci -
Day 3

HYBRID: Hybrid revascularization in patients with multi-vessel

We included 200 patients (100 with hybrid revascularization and 100 with conventional surgery). The complete revascularization rate...
solaci -
Day 3

FREEDOM: Insulin dependent versus non-insulin dependent with multivessel disease

From the total of 1900 patients in the FREEDOM study, 1248 did not require insulin (631 received...
solaci -
Day 3

OPTIMIZE: 3 versus 12 months dual antiplatelet therapy after angioplasty with DES

Currently the recommendation is 12 months of dual antiplatelet after a drug-eluting stent angioplasty. This study compared...
solaci -
Day 3

MOZART: IVUS reduces contrast volume needed for angioplasty

Contrast nephropathy is associated with increased morbidity and so this study evaluates the possibility of reducing the...
solaci -
Day 2

ADVISE II: iFFR comparable toFFRbut with out adenosine

Several studies tested the utility of fractional flow reserve (FFR) to assess coronary lesions functionally. The FFR...
solaci -